MVA-member company, Lund-based Alligator Bioscience, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead asset mitazalimab for the treatment of pancreatic cancer.
“This designation is a key milestone for our lead asset mitazalimab, which is producing outstanding clinical results in its Phase 2 trial in pancreatic cancer,” said Søren Bregenholt, CEO of Alligator Bioscience. “Orphan designation confers significant benefits in the form of cost savings during development and marketing exclusivity following approval, and we are very pleased to see the potential of mitazalimab being recognized with the award of this designation.”
Read full press release from Alligator Bioscience